The Future of Liver Transplantation

Transplantation Proceedings

Volumn 42, Issue 2, 2010, Pages 613-616

  Varo Perez E ^a   Castroagudin J F ^a  

^a Pediatric Nutrition Research Group Health Research Institute of Santiago de Compostela   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ALBUMIN DIALYSIS; ALLOGRAFT; ARTICLE; BILE DUCT CARCINOMA; BIOARTIFICIAL LIVER; BLOOD GROUP ABO INCOMPATIBILITY; BONE MARROW TRANSPLANTATION; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; DENDRITIC CELL; DISEASE SEVERITY; DRUG METABOLISM; GENETIC POLYMORPHISM; GRAFT RECIPIENT; HEPATITIS C; HLA MATCHING; HOSPITAL ADMISSION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER SUPPORT; LIVER TRANSPLANTATION; LIVER TUMOR; LIVING DONOR; LYMPHOCYTE DEPLETION; MEDICAL ETHICS; METABOLIC DISORDER; PHARMACOGENETICS; PHARMACOGENOMICS; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRIMARY TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; STEM CELL; SURGICAL TECHNIQUE; SURVIVAL; XENOTRANSPLANTATION;

EMERGENCIES; FORECASTING; GRAFT SURVIVAL; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVER, ARTIFICIAL; LIVING DONORS; REGISTRIES; SPAIN; SURVIVAL RATE; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 77949438531     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.02.003     Document Type: Article

References (25)

1. National Organization of Transplants. http://www.ont.es Accessed July 31, 2009
2. Perry I., and Neuberger J. Immunosuppression: towards a logical approach in liver transplantation. Clin Exp Inmunol 139 (2005) 2
3. Pageaux G.P., Rostaing L., Calmus Y., et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 12 (2006) 1755
4. Wiesner R.H., Shorr J.S., Steffen B.J., et al. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 11 (2005) 750
5. Pontón C., Vizcaíno L., Tomé S., et al. Conversion to mycophenolate mofetil combined with low doses of calcineurin inhibitors in liver transplant patients with chronic renal dysfunction. Transplantation 14 S1 (2008) S104
6. De Simone P., Carrai P., Precisi A., et al. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. Transpl Int 22 (2009) 278
7. Levy G., Schmidli H., Punch J., et al. Safety, tolerability, and efficacy of Everolimus in de novo liver transplant recipients12- and 36-month results. Liver Transplant 12 (2006) 1640
8. Castroagudin J.F., Molina E., Romero R., et al. Improvement of renal function after switching from calcineurin inhibitor to Everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl (2009) (in press)
9. Varo E., Bustamante M., and Fernández-Castroagudin J. Immunosupression in the immediate perioperative period after liver transplantation in patients with renal failure. Gastroenterol Hepatol 27 suppl 4 (2004) 87
10. Varo E., López A., and Rivero C. Initial immunosupression in liver transplant recipients with impaired renal function. Transplant Proc 37 (2005) 3909
11. Varo E., López A., Castroagudin J.F., et al. Alternative immunosupression for acute renal failure in liver transplantation: role of ultra-low tacrolimus and basiliximab. Transplant Proc 34 (2002) 1567
12. Castroagudín J.F., Molina E., Tomé S., et al. Safety of an inmmunosupressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence. Transplant Proc 41 (2009) 1003
13. Morioka D., Egawa H., Kasahara M., et al. Outcomes of adult-to-adult living donor liver transplantation: a single institution's experience wit 355 consecutive cases. Ann Surg 245 (2007) 315
14. Busuttil R.W., and Goss J.A. Split liver transplantation. Ann Surg 229 (1999) 313
15. Foley D.P., Fernandez L.A., Leverson G., et al. Donation after cardiac death: the University of Wisconsin experience with liver transplantation. Ann Surg 242 (2005) 724
16. López-Navidad A., and Caballero F. Extended criteria for organ accptance: strategies for achieving organ safety and for increasing organ pool. Clin Transplant 17 (2003) 308
17. Renz J.F., Kin C., Kinkhabwala M., et al. Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann Surg 242 (2005) 556
18. Cuende N., Grande L., Sanjuán F., et al. Liver transplant with organs from elderly donors: Spanish experience with more than 300 livers donors over 70 years of age. Transplantation 73 (2002) 1360
19. Tector A.J., Mangus R.S., Chestovich P., et al. Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival. Ann Surg 244 (2006) 439
20. De la Mata M., Cuende D., Huet J., et al. Model for end-stage liver disease score-based allocation of donors for liver transplantation: a spanish multicenter experience. Transplantation 82 (2006) 1429
21. Sociedad Española de Trasplante Hepático. Consensus document of the Spanish Society of Liver Transplantation. Gastroenterol Hepatol 31 (2008) 82
22. Hommman M., Kasakow L.B., Geoghegan J., et al. Aplication of MARS artificial liver support as bridging therapy before split liver retransplantation in a 15-month-old child. Pediatr Transplant 6 (2002) 340
23. Ott H.C., Matthiesen T.S., Goh S.K., et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Taylor D. Nat Med 14 (2008) 213
24. Heimbach J.K., Gores G.J., Haddock M.G., et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation 82 (2006) 1703
25. Villanueva A., Newell P., Chiang D.Y., et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27 (2007) 55